Abstract

Valley fever (VF) is difficult to diagnose, partly because the symptoms of VF are confounded with those of other communityacquired pneumonias. Confirmatory diagnostics detect IgM and IgG antibodies against coccidioidal antigens via immunodiffusion (ID). The false-negative rate can be as high as 50% to 70%, with 5% of symptomatic patients never showing detectable antibody levels. In this study, we tested whether the immunosignature diagnostic can resolve VF false negatives. An immunosignature is the pattern of antibody binding to random-sequence peptides on a peptide microarray. A 10,000-peptide microarray was first used to determine whether valley fever patients can be distinguished from 3 other cohorts with similar infections. After determining the VF-specific peptides, a small 96-peptide diagnostic array was created and tested. The performances of the 10,000-peptide array and the 96-peptide diagnostic array were compared to that of the ID diagnostic standard. The 10,000-peptide microarray classified the VF samples from the other 3 infections with 98% accuracy. It also classified VF falsenegative patients with 100% sensitivity in a blinded test set versus 28% sensitivity for ID. The immunosignature microarray has potential for simultaneously distinguishing valley fever patients from those with other fungal or bacterial infections. The same 10,000-peptide array can diagnose VF false-negative patients with 100% sensitivity. The smaller 96-peptide diagnostic array was less specific for diagnosing false negatives. We conclude that the performance of the immunosignature diagnostic exceeds that of the existing standard, and the immunosignature can distinguish related infections and might be used in lieu of existing diagnostics.

Original languageEnglish (US)
Pages (from-to)1169-1177
Number of pages9
JournalClinical and Vaccine Immunology
Volume21
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Coccidioidomycosis
Peptides
Microarrays
Immunodiffusion
Antibodies
Infection
Mycoses
Bacterial Infections
Immunoglobulin M
Pneumonia
Immunoglobulin G

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Application of immunosignatures for diagnosis of valley fever. / Navalkar, Krupa Arun; Johnston, Stephen; Woodbury, Neal; Galgiani, John N.; Magee, Dewey; Cichacz, Zbigniew; Stafford, Phillip.

In: Clinical and Vaccine Immunology, Vol. 21, No. 8, 2014, p. 1169-1177.

Research output: Contribution to journalArticle

Navalkar, Krupa Arun ; Johnston, Stephen ; Woodbury, Neal ; Galgiani, John N. ; Magee, Dewey ; Cichacz, Zbigniew ; Stafford, Phillip. / Application of immunosignatures for diagnosis of valley fever. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 8. pp. 1169-1177.
@article{b70f9c72c46944068802ab20544460c7,
title = "Application of immunosignatures for diagnosis of valley fever",
abstract = "Valley fever (VF) is difficult to diagnose, partly because the symptoms of VF are confounded with those of other communityacquired pneumonias. Confirmatory diagnostics detect IgM and IgG antibodies against coccidioidal antigens via immunodiffusion (ID). The false-negative rate can be as high as 50{\%} to 70{\%}, with 5{\%} of symptomatic patients never showing detectable antibody levels. In this study, we tested whether the immunosignature diagnostic can resolve VF false negatives. An immunosignature is the pattern of antibody binding to random-sequence peptides on a peptide microarray. A 10,000-peptide microarray was first used to determine whether valley fever patients can be distinguished from 3 other cohorts with similar infections. After determining the VF-specific peptides, a small 96-peptide diagnostic array was created and tested. The performances of the 10,000-peptide array and the 96-peptide diagnostic array were compared to that of the ID diagnostic standard. The 10,000-peptide microarray classified the VF samples from the other 3 infections with 98{\%} accuracy. It also classified VF falsenegative patients with 100{\%} sensitivity in a blinded test set versus 28{\%} sensitivity for ID. The immunosignature microarray has potential for simultaneously distinguishing valley fever patients from those with other fungal or bacterial infections. The same 10,000-peptide array can diagnose VF false-negative patients with 100{\%} sensitivity. The smaller 96-peptide diagnostic array was less specific for diagnosing false negatives. We conclude that the performance of the immunosignature diagnostic exceeds that of the existing standard, and the immunosignature can distinguish related infections and might be used in lieu of existing diagnostics.",
author = "Navalkar, {Krupa Arun} and Stephen Johnston and Neal Woodbury and Galgiani, {John N.} and Dewey Magee and Zbigniew Cichacz and Phillip Stafford",
year = "2014",
doi = "10.1128/CVI.00228-14",
language = "English (US)",
volume = "21",
pages = "1169--1177",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Application of immunosignatures for diagnosis of valley fever

AU - Navalkar, Krupa Arun

AU - Johnston, Stephen

AU - Woodbury, Neal

AU - Galgiani, John N.

AU - Magee, Dewey

AU - Cichacz, Zbigniew

AU - Stafford, Phillip

PY - 2014

Y1 - 2014

N2 - Valley fever (VF) is difficult to diagnose, partly because the symptoms of VF are confounded with those of other communityacquired pneumonias. Confirmatory diagnostics detect IgM and IgG antibodies against coccidioidal antigens via immunodiffusion (ID). The false-negative rate can be as high as 50% to 70%, with 5% of symptomatic patients never showing detectable antibody levels. In this study, we tested whether the immunosignature diagnostic can resolve VF false negatives. An immunosignature is the pattern of antibody binding to random-sequence peptides on a peptide microarray. A 10,000-peptide microarray was first used to determine whether valley fever patients can be distinguished from 3 other cohorts with similar infections. After determining the VF-specific peptides, a small 96-peptide diagnostic array was created and tested. The performances of the 10,000-peptide array and the 96-peptide diagnostic array were compared to that of the ID diagnostic standard. The 10,000-peptide microarray classified the VF samples from the other 3 infections with 98% accuracy. It also classified VF falsenegative patients with 100% sensitivity in a blinded test set versus 28% sensitivity for ID. The immunosignature microarray has potential for simultaneously distinguishing valley fever patients from those with other fungal or bacterial infections. The same 10,000-peptide array can diagnose VF false-negative patients with 100% sensitivity. The smaller 96-peptide diagnostic array was less specific for diagnosing false negatives. We conclude that the performance of the immunosignature diagnostic exceeds that of the existing standard, and the immunosignature can distinguish related infections and might be used in lieu of existing diagnostics.

AB - Valley fever (VF) is difficult to diagnose, partly because the symptoms of VF are confounded with those of other communityacquired pneumonias. Confirmatory diagnostics detect IgM and IgG antibodies against coccidioidal antigens via immunodiffusion (ID). The false-negative rate can be as high as 50% to 70%, with 5% of symptomatic patients never showing detectable antibody levels. In this study, we tested whether the immunosignature diagnostic can resolve VF false negatives. An immunosignature is the pattern of antibody binding to random-sequence peptides on a peptide microarray. A 10,000-peptide microarray was first used to determine whether valley fever patients can be distinguished from 3 other cohorts with similar infections. After determining the VF-specific peptides, a small 96-peptide diagnostic array was created and tested. The performances of the 10,000-peptide array and the 96-peptide diagnostic array were compared to that of the ID diagnostic standard. The 10,000-peptide microarray classified the VF samples from the other 3 infections with 98% accuracy. It also classified VF falsenegative patients with 100% sensitivity in a blinded test set versus 28% sensitivity for ID. The immunosignature microarray has potential for simultaneously distinguishing valley fever patients from those with other fungal or bacterial infections. The same 10,000-peptide array can diagnose VF false-negative patients with 100% sensitivity. The smaller 96-peptide diagnostic array was less specific for diagnosing false negatives. We conclude that the performance of the immunosignature diagnostic exceeds that of the existing standard, and the immunosignature can distinguish related infections and might be used in lieu of existing diagnostics.

UR - http://www.scopus.com/inward/record.url?scp=84906698523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906698523&partnerID=8YFLogxK

U2 - 10.1128/CVI.00228-14

DO - 10.1128/CVI.00228-14

M3 - Article

C2 - 24964807

AN - SCOPUS:84906698523

VL - 21

SP - 1169

EP - 1177

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 8

ER -